Biocon Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

This follows an earlier settlement that addressed the U.S. and Canadian markets.

The agreement clears the way for Biocon Biologics to commercialize Yesafili globally. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor used to treat multiple ophthalmology conditions, including neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV).

As part of the agreement, all pending litigation among Biocon Biologics, Regeneron, and Bayer has been dismissed. Biocon Biologics plans to launch Yesafili in the United Kingdom in January 2026, followed by launches in other settled countries in March 2026, or earlier in certain circumstances. The other terms of the settlement remain confidential.

The European Commission (EC) and the Medicines & Healthcare products Regulatory Agency (MHRA) have previously approved YESAFILI.

Yesafili has already received approval from the European Commission (EC) and the UK Medicines & Healthcare products Regulatory Agency (MHRA). Biocon Biologics had earlier secured market entry for the U.S. in April 2025, targeting the second half of calendar year 2026, and launched the product in Canada earlier this year, with market entry secured in March 2024.

Shreehas Tambe, CEO & managing director, Biocon Biologics, said, ?This settlement paves the way for Biocon Biologics to make available our biosimilar Aflibercept globally. This milestone expands our presence in the ophthalmology therapeutic area as we work closely with healthcare systems to increase access to patients everywhere.?

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.

On a consolidated basis, Biocon reported net profit of Rs 84.50 crore in Q2 September 2025 as against net loss of Rs 16 crore in Q2 September 2024. Net sales rose 20.24% YoY to Rs 4262.50 crore in Q2 September 2025.

The counter added 1.34% to currently trade at Rs 386.65 on the BSE.

Powered by Capital Market - Live News

Biocon announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 31 December 2025.

Powered by Capital Market - Live News

Biocon announced a strategic corporate action to fully integrate Biocon Biologics (BBL) as a wholly owned subsidiary into Biocon, subject to applicable approvals.

The Strategy Committee, constituted in May 2025, undertook a comprehensive evaluation of multiple strategic options for Biocon Biologics, including an IPO and a merger with Biocon. After careful consideration of key parameters such as strategic alignment, sectoral dynamics, shareholder value creation, and other relevant data, the Committee concluded that full integration of Biocon Biologics with Biocon and making Biocon Biologics a wholly owned subsidiary of Biocon through the acquisition of minority stakes offers the most efficient and value-accretive path forward.

Under the proposed transaction,

A) Biocon will acquire the remaining stake in Biocon Biologics from Serum Institute Life Sciences (Serum), Tata Capital Growth Fund II (Tata Capital) and Activ Pine LLP (Activ Pine) through a share swap of 70.28 Biocon shares for every 100 Biocon Biologics shares, at a share price of INR 405.78 per Biocon share; valuing Biocon Biologics at USD 5.5 billion.

B) Further, Biocon will acquire the residual stake held by Mylan Inc. (Viatris) for a total consideration of USD 815 million, of which USD 400 million will be payable in cash and USD 415 million through a share swap of 61.70 Biocon shares for every 100 Biocon Biologics shares at a share price of INR 405.78 per Biocon share.

C) The swap ratios have been approved by the Board based on independent valuations by EY.

The Board has also approved raising additional capital, of up to Rs 4500 crore (USD 500 million) through Qualified Institutional Placement (QIP), subject to shareholder approval. The proceeds of the QIP will be largely utilised towards the cash component payable to Viatris.

The integration process is expected to be completed no later than 31 March 2026.

Siddharth Mittal and Shreehas Tambe will continue in their roles as CEO & Managing Director at Biocon and Biocon Biologics, respectively, until completion of the integration process.

Post the integration and upon execution of the necessary documentation, receipt of approvals from the Nomination & Remuneration Committee and the Board, Shreehas Tambe will take on the role of CEO & Managing Director and Kedar Upadhye the role of Chief Financial Officer of the combined business. Siddharth Mittal, CEO & Managing Director, Biocon, will transition into a leadership role within the Group.

Commenting on the corporate action, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said: ?The integration of Biocon Biologics Limited into Biocon Limited represents the next chapter in our evolution. Strategically, Biocon will be one of the few companies offering both biosimilars and generics at a global scale. As the only company with biosimilar insulins and generic GLP1 peptides, Biocon is uniquely positioned to comprehensively address the needs of patients living with diabetes. Together with our combined oncology and immunology portfolios, this creates a differentiated offering addressing the world's most pressing healthcare needs. I am also pleased to announce that Shreehas Tambe will lead the Transition and Integration Management Committee and will take over as the CEO & Managing Director of the combined business, subject to requisite approvals. His 28 years of experience with the Biocon Group will be invaluable as we advance our mission to make lifesaving medicines affordable and accessible to patients worldwide.?

Powered by Capital Market - Live News

Biocon will hold a meeting of the Board of Directors of the Company on 6 December 2025.

Powered by Capital Market - Live News